Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458740 | 1.00 | PDK2 (0.44) | PDK2SMN1; SMN2HPGDNPSR1MAOB | |
| SCHEMBL21071663 | 0.99 | PDK2 (0.45) | PDK2SMN1; SMN2HPGDNPSR1MAOB | |
| SCHEMBL21997754 | 0.92 | SMN1; SMN2 (0.42) | PDK2SMN1; SMN2HPGDNPSR1MAOB | |
| SCHEMBL20067563 | 0.89 | ACHE (0.42) | PDK2SMN1; SMN2HPGDNPSR1MAOB | |
| SCHEMBL3485869 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDNPSR1GAARAB9A | |
| SCHEMBL14554544 | 0.87 | MAOB (0.49) | PDK2SMN1; SMN2MAOBGAATDP1 | |
| SCHEMBL15996418 | 0.85 | MAOB (0.51) | MAOBPOLB | |
| SCHEMBL2399096 | 0.84 | MAOB (0.52) | MAOB | |
| SCHEMBL31439940 | 0.84 | MAOB (0.52) | MAOB | |
| SCHEMBL21459052 | 0.84 | MAOB (0.51) | SMN1; SMN2HPGDNPSR1MAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210121462-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2020023813-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | ITPA, POLR2H, POLR2E | PDK2 509/4885SMN1; SMN2 2913/4885HPGD 472/4885 |
| US-20210121462-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | PIR, PNPO, IDO1 | PDK2 377/4885SMN1; SMN2 4681/4885HPGD 1163/4885 |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | ITPA, POLR2H, POLR2E | PDK2 509/4885SMN1; SMN2 2913/4885HPGD 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.